Comprehensive lung injury pathology induced by mTOR inhibitors

Overview of attention for article published in Clinical and Translational Oncology, August 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

patent: 8 patents

wikipedia: 3 Wikipedia pages

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 19 Mendeley

Summary Patents Wikipedia Dimensions citations

So far, Altmetric has seen 8 patents that reference this research output.

Rapamycin for the treatment of lymphangioleiomyomatosis

Grant US-11744797-B2

United States of America

Inhalable rapamycin formulation for treating age-related conditions

Grant US-11648199-B2

United States of America

Inhalable rapamycin formulation for the treatment of pulmonary hypertension

Grant US-11491143-B2

United States of America

Rapamycin for the treatment of lymphangioleiomyomatosis

Grant US-11123289-B2

United States of America

Inhalable rapamycin formulation for treating age-related conditions

Grant US-11103449-B2

United States of America

Rapamycin for the treatment of lymphangioleiomyomatosis

Application US-10307371-B2

United States of America

Rapamycin for the treatment of lymphangioleiomyomatosis

Application US-10307370-B2

United States of America

Rapamycin powders for pulmonary delivery

Application US-9387169-B2

United States of America